Advertisement

Topics

MeiraGTx Limited Company Profile

09:48 EDT 23rd June 2018 | BioPortfolio

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing potential treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also developing potential treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers, as well as certain neurodegenerative diseases. In addition, MeiraGTx is developing novel gene regulation platforms that it believes will potentially transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.


News Articles [50 Associated News Articles listed on BioPortfolio]

MeiraGTx Files for an $86 Million IPO

MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).

Gene therapy start-up MeiraGTx nets $80.2mm in Nasdaq IPO

In its initial public offering on the Nasdaq Exchange, MeiraGTx Holdings PLC (developing AAV gene therapies) netted $80.2mm through the sale of 5.75mm shares (including the overallotment) at $15, the ...

MeiraGTx's AAV-RPGR for retinitis pigmentosa gets fast track designation

The FDA has granted fast track designation to AAV-RPGR for the treatment of X-linked retinitis pigmentosa, MeiraGTx announced in a press release.The fast track process will allow MeiraGTx to have earl...

MeiraGTx proposes $86.3M IPO

MeiraGTx ticks up after $75M IPO

MeiraGTx plans IPO

MeiraGTx raises $75M in IPO

FDA Grants Fast Track Status to MeiraGTx’s AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiency

LONDON & NEW YORK–(BUSINESS WIRE)–MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has g...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [84 Associated Companies listed on BioPortfolio]

MeiraGTx

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing pote...

MeiraGTx Limited

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing pote...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

More Information about "MeiraGTx Limited" on BioPortfolio

We have published hundreds of MeiraGTx Limited news stories on BioPortfolio along with dozens of MeiraGTx Limited Clinical Trials and PubMed Articles about MeiraGTx Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MeiraGTx Limited Companies in our database. You can also find out about relevant MeiraGTx Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record